Amedeo Smart

Free Medical Literature Service

 

Amedeo

Rabies
  Free Subscription

Articles published in
Vaccine
    February 2024
  1. TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
    Rabies vaccination of the Maxakali indigenous population.
    Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2024
  2. CAO H, Li H, Luan N, Zhang H, et al
    A rabies mRNA vaccine with H270P mutation in its glycoprotein induces strong cellular and humoral immunity.
    Vaccine. 2024 Jan 22:S0264-410X(24)00069-0. doi: 10.1016/j.vaccine.2024.
    >> Share

    December 2023
  3. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    >> Share

    November 2023
  4. TECHAKRIENGKRAI N, Aryuman S, Vanlarat K, Karnchanapraphas C, et al
    Impacts of shelter management on canine rabies immune status.
    Vaccine. 2023 Nov 9:S0264-410X(23)01330-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  5. HAEDER SF
    Assessing vaccine hesitancy and support for vaccination requirements for pets and potential Spillovers from humans.
    Vaccine. 2023 Nov 5:S0264-410X(23)01263-X. doi: 10.1016/j.vaccine.2023.
    >> Share

    October 2023
  6. MULLER T, Wallace RM, Freuling CM
    Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
    Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
    >> Share

  7. HONGTU Q, BoLi L, Jianguo C, Shusheng P, et al
    Immunogenicity of rabies virus G mRNA formulated with lipid nanoparticles and nucleic acid immunostimulators in mice.
    Vaccine. 2023 Oct 20:S0264-410X(23)01191-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  8. YU P, Liu Y, Tao X, He Y, et al
    Potential option for rabies post-exposure prophylaxis: New vaccine with PIKA adjuvant against diverse Chinese rabies strains.
    Vaccine. 2023 Oct 9:S0264-410X(23)01161-1. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2023
  9. LUGELO A, Hampson K, McElhinney LM, Lankester F, et al
    Evaluation of an iELISA for detection and quantification of rabies antibodies in domestic dog sera.
    Vaccine. 2023 Sep 14:S0264-410X(23)01058-7. doi: 10.1016/j.vaccine.2023.
    >> Share

    July 2023
  10. IZUMI F, Miyamoto S, Masatani T, Sasaki M, et al
    Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs.
    Vaccine. 2023 Jul 1:S0264-410X(23)00779-X. doi: 10.1016/j.vaccine.2023.
    >> Share

    September 2022
  11. LI L, Li Y, Bai Y, Li G, et al
    Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: A phase b randomized, double-blind, parallel-controlled study.
    Vaccine. 2022 Sep 16. pii: S0264-410X(22)01114.
    >> Share

    August 2022
  12. QUIAMBAO BP, Lim JG, Bosch Castells V, Augard C, et al
    One-week intramuscular or intradermal pre-exposure prophylaxis with human diploid cell vaccine or Vero cell rabies vaccine, followed by simulated post-exposure prophylaxis at one year: A phase III, open-label, randomized, controlled trial to assess im
    Vaccine. 2022 Aug 3. pii: S0264-410X(22)00923.
    >> Share

    July 2022
  13. QUIAMBAO B, Montalban C, Minutello AM, Guinet-Morlot F, et al
    Serum-free purified Vero rabies vaccine is safe and immunogenic in children: Results of a randomized phaseII pre-exposure prophylaxis regimen study.
    Vaccine. 2022 Jul 26. pii: S0264-410X(22)00830.
    >> Share

    June 2022
  14. PICHON S, Moureau A, Petit C, Chu L, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in healthy adults: A randomised phase II pre-exposure prophylaxis study.
    Vaccine. 2022 Jun 28. pii: S0264-410X(22)00806.
    >> Share

  15. WANG L, Zhang J, Meng S, Ge L, et al
    Safety and immunogenicity of human rabies vaccine for the Chinese population after PEP: A systematic review and meta-analysis.
    Vaccine. 2022 Jun 21. pii: S0264-410X(22)00784.
    >> Share

    November 2021
  16. YE K, Shi D, Zhang Z, Bian L, et al
    A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine.
    Vaccine. 2021 Nov 20. pii: S0264-410X(21)01393.
    >> Share

    September 2021
  17. MCCLAIN JB, Chuang A, Reid C, Moore SM, et al
    Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
    Vaccine. 2021 Sep 2. pii: S0264-410X(21)01114.
    >> Share

    June 2021
  18. ODITA CI, Conan A, Smith-Antony M, Battice J, et al
    Non-specific effects of rabies vaccine on the incidence of self-reported common infectious disease episodes: A randomized controlled trial.
    Vaccine. 2021 Jun 11. pii: S0264-410X(21)00719.
    >> Share

  19. ITO N, Okamoto T, Sasaki M, Miyamoto S, et al
    Safety enhancement of a genetically modified live rabies vaccine strain by introducing an attenuating Leu residue at position 333 in the glycoprotein.
    Vaccine. 2021 Jun 3. pii: S0264-410X(21)00553.
    >> Share

    April 2021
  20. JENSEN KJ, Tolstrup LK, Knobel DL, Aaby P, et al
    Non-specific effects of maternal and offspring rabies vaccination on mortality and antibiotic use in a Danish pig herd: A randomized trial.
    Vaccine. 2021 Apr 9. pii: S0264-410X(21)00399.
    >> Share

  21. SMITH TG, Fooks AR, Moore SM, Freuling CM, et al
    Negligible risk of rabies importation in dogs thirty days after demonstration of adequate serum antibody titer.
    Vaccine. 2021 Apr 4. pii: S0264-410X(21)00368.
    >> Share

    January 2021
  22. KNOBEL DL, Arega SM, Conan A
    Sex-differential non-specific effects of rabies vaccine in dogs: An extended analysis of a randomized controlled trial in a high-mortality population.
    Vaccine. 2021 Jan 22. pii: S0264-410X(21)00045.
    >> Share

  23. ALDRICH C, Leroux-Roels I, Huang KB, Bica MA, et al
    Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial.
    Vaccine. 2021 Jan 21. pii: S0264-410X(20)31667.
    >> Share

  24. XU C, Lau CL, Clark J, Rafferty AC, et al
    Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis.
    Vaccine. 2021 Jan 18. pii: S0264-410X(21)00039.
    >> Share

    July 2020
  25. TROTTER C, Abela-Ridder B, Bharti O, Knopf L, et al
    Reply to 'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5580-5581.
    >> Share

  26. SOENTJENS P, Van Damme P, Bottieau E
    'Alternative abridged preventive regimens against rabies for children in high endemic countries'.
    Vaccine. 2020;38:5578-5579.
    >> Share

    June 2020
  27. UNDURRAGA EA, Millien MF, Allel K, Etheart MD, et al
    Costs and effectiveness of alternative dog vaccination strategies to improve dog population coverage in rural and urban settings during a rabies outbreak.
    Vaccine. 2020 Jun 29. pii: S0264-410X(20)30767.
    >> Share

  28. PARIZE P, Poujol P, Morineau Le Houssine P, Goesch J, et al
    Immune response to rabies post-exposure prophylaxis in patients with non-HIV secondary immunodeficiencies.
    Vaccine. 2020 Jun 22. pii: S0264-410X(20)30823.
    >> Share

  29. ANGSUWATCHARAKON P, Ratananpinit N, Yoksan S, Saengseesom W, et al
    Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country.
    Vaccine. 2020 Jun 7. pii: S0264-410X(20)30699.
    >> Share

  30. BONWITT J, Bonaparte S, Blanton J, Gibson AD, et al
    Oral bait preferences and feasibility of oral rabies vaccination in Bangladeshi dogs.
    Vaccine. 2020 Jun 5. pii: S0264-410X(20)30692.
    >> Share

    May 2020
  31. MORGENROTH A, Jakel V, Hanke-Robinson H, Muller T, et al
    A novel electrophoretic immunoblot as antigen desorption and quantification method for alum-adjuvanted veterinary rabies vaccines.
    Vaccine. 2020 May 8. pii: S0264-410X(20)30561.
    >> Share

  32. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Single-visit, 4-site intradermal (ID) rabies vaccination induces robust immune responses 5 years after 1-week, 4-site ID primary post-exposure prophylaxis in the Philippines.
    Vaccine. 2020;38:3740-3746.
    >> Share

    September 2019
  33. LUO J, Zhang Y, He H, Liu Q, et al
    Artesunate enhances the immune response of rabies vaccine as an adjuvant.
    Vaccine. 2019 Sep 30. pii: S0264-410X(19)31305.
    >> Share

    August 2019
  34. SREENIVASAN N, Li A, Shiferaw M, Tran CH, et al
    Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)30475.
    >> Share

  35. ZHAO R, Yu P, Shan Y, Thirumeni N, et al
    Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects.
    Vaccine. 2019 Aug 27. pii: S0264-410X(19)31107.
    >> Share

  36. BHARTI OK, Thakur B, Rao R
    Wound-only injection of rabies immunoglobulin (RIG) saves lives and costs less than a dollar per patient by "pooling strategy".
    Vaccine. 2019 Aug 5. pii: S0264-410X(19)31008.
    >> Share

    July 2019
  37. JANEWONGWIROT P, Jantarabenjakul W, Anugulruengkitt S, Anunsittichai O, et al
    A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children.
    Vaccine. 2019 Jul 26. pii: S0264-410X(19)30953.
    >> Share

  38. WAMBURA G, Mwatondo A, Muturi M, Nasimiyu C, et al
    Rabies vaccine and immunoglobulin supply and logistics: Challenges and opportunities for rabies elimination in Kenya.
    Vaccine. 2019 Jul 17. pii: S0264-410X(19)30659.
    >> Share

  39. TRABELSI K, Ben Zakour M, Kallel H
    Purification of rabies virus produced in Vero cells grown in serum free medium.
    Vaccine. 2019 Jul 9. pii: S0264-410X(19)30849.
    >> Share

    June 2019
  40. SOBEY KG, Jamieson SE, Walpole AA, Rosatte RC, et al
    ONRAB(R) oral rabies vaccine is shed from, but does not persist in, captive mammals.
    Vaccine. 2019 Jun 24. pii: S0264-410X(19)30808.
    >> Share

  41. GUO Z, Bai L, Gong S
    Some comments on the scandal of rabies vaccine in China.
    Vaccine. 2019 Jun 13. pii: S0264-410X(19)30732.
    >> Share

  42. ROUROU S, Ben Zakkour M, Kallel H
    Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
    Vaccine. 2019 Jun 11. pii: S0264-410X(19)30749.
    >> Share

    May 2019
  43. FORRO B, Marton S, Kecskemeti S, Hornyak A, et al
    Vaccine-associated rabies in red fox, Hungary.
    Vaccine. 2019 May 17. pii: S0264-410X(19)30628.
    >> Share

    March 2019
  44. WENTWORTH D, Hampson K, Thumbi SM, Mwatondo A, et al
    A social justice perspective on access to human rabies vaccines.
    Vaccine. 2019 Mar 27. pii: S0264-410X(19)30150.
    >> Share

  45. TAYLOR E, Banyard AC, Bourhy H, Cliquet F, et al
    Avoiding preventable deaths: The scourge of counterfeit rabies vaccines.
    Vaccine. 2019 Mar 25. pii: S0264-410X(19)30369.
    >> Share

  46. QUIAMBAO BP, Ambas C, Diego S, Bosch Castells V, et al
    Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Vaccine. 2019 Mar 16. pii: S0264-410X(19)30335.
    >> Share

  47. CHEN T, Zhou X, Qi Y, Mi L, et al
    Feline herpesvirus vectored-rabies vaccine in cats: A dual protection.
    Vaccine. 2019 Mar 13. pii: S0264-410X(19)30310.
    >> Share

    February 2019
  48. DOENER F, Hong HS, Meyer I, Tadjalli-Mehr K, et al
    RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial.
    Vaccine. 2019 Feb 21. pii: S0264-410X(19)30219.
    >> Share

  49. KESSELS J, Tarantola A, Salahuddin N, Blumberg L, et al
    Rabies post-exposure prophylaxis: A systematic review on abridged vaccination schedules and the effect of changing administration routes during a single course.
    Vaccine. 2019 Feb 5. pii: S0264-410X(19)30105.
    >> Share

  50. TRAN CH, Afriyie DO, Pham TN, Otsu S, et al
    Rabies post-exposure prophylaxis initiation and adherence among patients in Vietnam, 2014-2016.
    Vaccine. 2019 Feb 2. pii: S0264-410X(19)30093.
    >> Share

    January 2019
  51. WARRELL MJ
    Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen.
    Vaccine. 2019 Jan 25. pii: S0264-410X(19)30073.
    >> Share

  52. RUPPRECHT CE, Kuzmin IV, Yale G, Nagarajan T, et al
    Priorities in applied research to ensure programmatic success in the global elimination of canine rabies.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30068.
    >> Share

    December 2018
  53. RYSAVA K, Miranda ME, Zapatos R, Lapiz S, et al
    On the path to rabies elimination: The need for risk assessments to improve administration of post-exposure prophylaxis.
    Vaccine. 2018 Dec 17. pii: S0264-410X(18)31627.
    >> Share

  54. ANOTHAISINTAWEE T, Julienne Genuino A, Thavorncharoensap M, Youngkong S, et al
    Cost-effectiveness modelling studies of all preventive measures against rabies: A systematic review.
    Vaccine. 2018 Dec 13. pii: S0264-410X(18)31634.
    >> Share

  55. DENIS M, Knezevic I, Wilde H, Hemachudha T, et al
    An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route.
    Vaccine. 2018 Dec 11. pii: S0264-410X(18)31635.
    >> Share

  56. HAMPSON K, Abela-Ridder B, Bharti O, Knopf L, et al
    Modelling to inform prophylaxis regimens to prevent human rabies.
    Vaccine. 2018 Dec 7. pii: S0264-410X(18)31519.
    >> Share

  57. RATTANAVIPAPONG W, Thavorncharoensap M, Youngkong S, Genuino AJ, et al
    The impact of transmission dynamics of rabies control: Systematic review.
    Vaccine. 2018 Dec 5. pii: S0264-410X(18)31558.
    >> Share

    November 2018
  58. RAJEEV M, Edosoa G, Hanitriniaina C, Andriamandimby SF, et al
    Healthcare utilization, provisioning of post-exposure prophylaxis, and estimation of human rabies burden in Madagascar.
    Vaccine. 2018 Nov 30. pii: S0264-410X(18)31520.
    >> Share

  59. SPARROW E, Torvaldsen S, Newall AT, Wood JG, et al
    Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline.
    Vaccine. 2018 Nov 29. pii: S0264-410X(18)31503.
    >> Share

  60. TARANTOLA A, Tejiokem MC, Briggs DJ
    Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31542.
    >> Share

  61. TARANTOLA A, Ly S, Chan M, In S, et al
    Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014.
    Vaccine. 2018 Nov 16. pii: S0264-410X(18)31420.
    >> Share

  62. IVES A, Dieuzy-Labaye I, Abela-Ridder B
    Global characteristics of the rabies biologics market in 2017.
    Vaccine. 2018 Nov 9. pii: S0264-410X(18)31364.
    >> Share

    October 2018
  63. O'BRIEN KL, Nolan T
    The WHO position on rabies immunization - 2018 updates.
    Vaccine. 2018 Oct 17. pii: S0264-410X(18)31366.
    >> Share

  64. LI AJ, Sreenivasan N, Siddiqi UR, Tahmina S, et al
    Descriptive assessment of rabies post-exposure prophylaxis procurement, distribution, monitoring, and reporting in four Asian countries: Bangladesh, Bhutan, Cambodia, and Sri Lanka, 2017-2018.
    Vaccine. 2018 Oct 9. pii: S0264-410X(18)31363.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016